A Phase 2 interventional study of Debio 1450 IV and Debio 1450 Oral in Bacterial Infections, sponsored by Debiopharm International SA. Completed at 22 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-11-13.
Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.
Among the 181 studies in Bacterial Infections with a site in United States, this one is the 31st largest by enrollment of the 151 interventional ones that give a count, is one of 9 that started in 2015, is one of 26 in phase 2, and was the 91st registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:
Nanopath, Inc · Sites in United States
Ages 18+ · Women only
Bausch Health Americas, Inc. · Sites in United States
Ages 6–12
Karius, Inc. · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
Baxis Pharmaceuticals, Inc. · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
181 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 67 · Phase 2 27 · Phase 3 24 · Phase 4 15
First in 1997; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 330 is above the median of 84 across 382 interventional studies indexed under Bacterial Infections.
Median enrollment 62 across the 151 interventional studies, 200 across the 29 observational. Of the 160 that completed or were terminated, 58 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
102 of 181 have an industry lead sponsor. The 10 most frequent:
This study is registered under Debiopharm International SA, one of the names counted as Debiopharm. Under that name alone:
Debiopharm International SA is the lead sponsor of 51 studies on the registry; 6 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Debiopharm has 3 studies filed under Bacterial Infections — fewer than ten, so there is no comparison to draw.
7 of the studies in Bacterial Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07607470Nanopath, IncLarge Algorithm Setting and Validation Study | 2026-12 |
| NCT06070688The University of Texas Health Science Center, HoustonAn Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED. | 2026-12-31 |
| NCT07285785Bausch Health Americas, Inc.Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea | 2027-04-20 |
| NCT05846399University of Missouri-ColumbiaCAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE) | 2027-07-01 |
| NCT07371429GlaxoSmithKlineA Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics | 2027-08-23 |
Add all 7 to your calendar (.ics) → With an account.
Among the 181 studies in Bacterial Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of 2 different doses of intravenous and oral Debio 1450 compared with intravenous vancomycin and oral linezolid in the treatment of patients with staphylococcal ABSSSI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).
Drug: Debio 1450 IV · Drug: Debio 1450 Oral · Drug: Linezolid Placebo
After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.
Drug: Debio 1450 IV · Drug: Debio 1450 Oral · Drug: Debio 1450 Oral Placebo · Drug: Linezolid Placebo
After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.
Drug: Linezolid · Drug: Debio 1450 Oral Placebo · Drug: Vancomycin IV
Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).
Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.
Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
Linezolid placebo will be supplied as film-coated compressed tablets.
Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator
ECRR was defined as the percentage of responders to treatment at 48 to 72 hours from randomization. Responders were the participants who showed greater than or equal to (≥) 20% reduction in area of the primary lesion involving erythema, edema, or induration of the primary ABSSSI lesion (as assessed by the ruler method) at 48 to 72 hours compared to baseline.
Time frame: At 48 to 72 hours from randomization (Day 4)
Clinical Success Rate: Percentage of Participants Assessed by the Investigator as Responders at 48 to 72 Hours From Randomization, at End of Treatment (EOT) and Short-term Follow-up (STFU)
The Investigator Assessment of Clinical Outcome (IACO) of treatment was assessed for each participant as success or failure at 48 to 72 hours after randomization at EOT and STFU visits. Clinical success was resolution or near resolution of most disease-specific signs and symptoms and no new signs, symptoms, or complications attributable to ABSSSI such that no further antibiotic therapy is required for treatment of original site of infection. Clinical failure was requirement for additional antibiotic therapy for treatment of the original site of infection or incision and drainage of ABSSSI site that was not both anticipated and completed within a 48- to 72-hour window following randomization, or unplanned major surgical intervention required due to failure of study medication or development of osteomyelitis after baseline. Participants who met both success criteria and none of failure criteria were considered as a clinical success for IACO.
Time frame: 48 to 72 hours after randomization (Day 4), EOT (Day 12) and STFU (Day 19)
Clinical Success Rate: Percentage of Participants Assessed by the Sponsor as Responders After 7 to 10 Days of Treatment at EOT and STFU
The Sponsor's Assessment of Clinical Outcome was obtained at EOT and STFU visits based on IACO and additional criteria. Sponsor assessed participants as clinical failure if they required non-study or rescue antibiotics due to lack of efficacy after at least 48 hours from randomization or experienced drug-related serious adverse events (SAEs) or discontinuation of study medication for drug-related AEs or required antibiotic therapy for longer than 10 days or had the need for unplanned surgical intervention \>48 hours after randomization. As per IACO, clinical success was resolution or near resolution of most disease-specific signs and symptoms and no new signs, symptoms or complications. Clinical failure was requirement for additional antibiotic therapy or incision and drainage of ABSSSI site or unplanned major surgical intervention or development of osteomyelitis.
Time frame: EOT (Day 12) and STFU (Day 19)
Percentage of Participants With a Composite Assessment of Clinical Outcome (CACO) of Success
CACO of treatment was determined as a combined outcome of early response to treatment (at 48 to 72 hours from randomization) and IACO at the STFU visit. Participants had a CACO of success if they met both of the following criteria: An early response to treatment (at 48 to 72 hours from randomization) (ECR = responder) and a clinical outcome of success at the STFU visit (7 to 14 days after EOT) based on IACO (IACO = success).
Time frame: 48 to 72 hours after randomization (Day 4) and STFU (Day 19)
Percentage of Participants Who Showed Microbiological Evidence of Cure 48 to 72 Hours From Randomization, EOT, and STFU
The microbiological outcome was assessed by the sponsor at 48 to 72 hours from randomization, EOT and STFU. It was based on blood and skin lesion identification results from baseline samples and skin lesion identification results from baseline samples and skin lesion identification results from follow-up samples as well as on, molecular typing results, and the IACO. Microbiological eradication rate was defined as proportion of participants with 'Documented Eradication' (absence of baseline pathogen(s) in follow-up cultures of the original site of infection.) or 'Presumed Eradication' (no material available for culture and an IACO of 'Success') in relation to the total number of participants in the respective treatment group.
Time frame: 48 to 72 hours after randomization (Day 4), EOT (Day 12) and STFU (Day 19)
Participants took part in the study in the United States, from 14 May 2015 to 12 September 2016. Of the 505 participants screened, 175 discontinued from the study prior to randomization and 330 were randomized.
| Milestone | Debio 1450 80 mg (Milligrams)/120 mg BID | Debio 1450 160 mg/240 mg BID | Vancomycin/Linezolid BID |
|---|---|---|---|
| Started | 110 | 109 | 111 |
| Safety population | 110 | 107 | 107 |
| Completed | 93 | 90 | 97 |
| Not completed | 17 | 19 | 14 |
| Withdrew: Adverse event | 2 | 2 | 0 |
| Withdrew: Physician decision | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 5 | 5 | 4 |
| Withdrew: Other | 9 | 11 | 9 |
ECRR was defined as the percentage of responders to treatment at 48 to 72 hours from randomization. Responders were the participants who showed greater than or equal to (≥) 20% reduction in area of the primary lesion involving erythema, edema, or induration of the primary ABSSSI lesion (as assessed by the ruler method) at 48 to 72 hours compared to baseline.
| percentage of participants | Debio 1450 80 mg/120 mg BID | Debio 1450 160 mg/240 mg BID | Vancomycin/Linezolid BID |
|---|---|---|---|
| Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator | 94.6 | 90.1 | 91.1 |
The Investigator Assessment of Clinical Outcome (IACO) of treatment was assessed for each participant as success or failure at 48 to 72 hours after randomization at EOT and STFU visits. Clinical success was resolution or near resolution of most disease-specific signs and symptoms and no new signs, symptoms, or complications attributable to ABSSSI such that no further antibiotic therapy is required for treatment of original site of infection. Clinical failure was requirement for additional antibiotic therapy for treatment of the original site of infection or incision and drainage of ABSSSI site that was not both anticipated and completed within a 48- to 72-hour window following randomization, or unplanned major surgical intervention required due to failure of study medication or development of osteomyelitis after baseline. Participants who met both success criteria and none of failure criteria were considered as a clinical success for IACO.
| percentage of participants | Debio 1450 80 mg/120 mg BID | Debio 1450 160 mg/240 mg BID | Vancomycin/Linezolid BID |
|---|---|---|---|
| 48 to 72 hours after randomization | 83.7 | 81.3 | 86.1 |
| EOT | 92.4 | 87.9 | 92.1 |
| STFU | 84.8 | 83.5 | 92.1 |
The Sponsor's Assessment of Clinical Outcome was obtained at EOT and STFU visits based on IACO and additional criteria. Sponsor assessed participants as clinical failure if they required non-study or rescue antibiotics due to lack of efficacy after at least 48 hours from randomization or experienced drug-related serious adverse events (SAEs) or discontinuation of study medication for drug-related AEs or required antibiotic therapy for longer than 10 days or had the need for unplanned surgical intervention \>48 hours after randomization. As per IACO, clinical success was resolution or near resolution of most disease-specific signs and symptoms and no new signs, symptoms or complications. Clinical failure was requirement for additional antibiotic therapy or incision and drainage of ABSSSI site or unplanned major surgical intervention or development of osteomyelitis.
| percentage of participants | Debio 1450 80 mg/120 mg BID | Debio 1450 160 mg/240 mg BID | Vancomycin/Linezolid BID |
|---|---|---|---|
| EOT | 89.1 | 86.8 | 90.1 |
| STFU | 81.5 | 81.3 | 90.1 |
CACO of treatment was determined as a combined outcome of early response to treatment (at 48 to 72 hours from randomization) and IACO at the STFU visit. Participants had a CACO of success if they met both of the following criteria: An early response to treatment (at 48 to 72 hours from randomization) (ECR = responder) and a clinical outcome of success at the STFU visit (7 to 14 days after EOT) based on IACO (IACO = success).
| percentage of participants | Debio 1450 80 mg/120 mg BID | Debio 1450 160 mg/240 mg BID | Vancomycin/Linezolid BID |
|---|---|---|---|
| Percentage of Participants With a Composite Assessment of Clinical Outcome (CACO) of Success | 83.7 | 81.3 | 88.1 |
The microbiological outcome was assessed by the sponsor at 48 to 72 hours from randomization, EOT and STFU. It was based on blood and skin lesion identification results from baseline samples and skin lesion identification results from baseline samples and skin lesion identification results from follow-up samples as well as on, molecular typing results, and the IACO. Microbiological eradication rate was defined as proportion of participants with 'Documented Eradication' (absence of baseline pathogen(s) in follow-up cultures of the original site of infection.) or 'Presumed Eradication' (no material available for culture and an IACO of 'Success') in relation to the total number of participants in the respective treatment group.
| percentage of participants | Debio 1450 80 mg/120 mg BID | Debio 1450 160 mg/240 mg BID | Vancomycin/Linezolid BID |
|---|---|---|---|
| 48 to 72 hours after randomization | 72.8 | 69.2 | 75.2 |
| EOT | 92.4 | 86.8 | 91.1 |
| STFU | 84.8 | 83.5 | 91.1 |
Collected over 21 days after EOT (Day 33). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Debio 1450 80 mg/120 mg BID | — | 2/110 (1.8%) | 18/110 (16.4%) |
| Debio 1450 160 mg/240 mg BID | — | 1/107 (0.9%) | 29/107 (27.1%) |
| Vancomycin/Linezolid BID | — | 1/107 (0.9%) | 20/107 (18.7%) |
| Event | Debio 1450 80 mg/120 mg BID | Debio 1450 160 mg/240 mg BID | Vancomycin/Linezolid BID |
|---|---|---|---|
| Skin infectionInfections and infestations | 2/110 | 0/107 | 0/107 |
| CellulitisInfections and infestations | 0/110 | 0/107 | 1/107 |
| OverdoseInjury, poisoning and procedural complications | 0/110 | 1/107 | 0/107 |
| Event | Debio 1450 80 mg/120 mg BID | Debio 1450 160 mg/240 mg BID | Vancomycin/Linezolid BID |
|---|---|---|---|
| HeadacheNervous system disorders | 10/110 | 18/107 | 9/107 |
| NauseaGastrointestinal disorders | 7/110 | 9/107 | 7/107 |
| DiarrhoeaGastrointestinal disorders | 3/110 | 3/107 | 6/107 |
| VomitingGastrointestinal disorders | 1/110 | 6/107 | 2/107 |
| AbscessInfections and infestations | 3/110 | 6/107 | 0/107 |
Intent-to-Treat Population (ITT) population included all randomized participants.
| Age, Continuous(years) | Debio 1450 80 mg/120 mg BID | Debio 1450 160 mg/240 mg BID | Vancomycin/Linezolid BID | Total |
|---|---|---|---|---|
| Mean | 43.9 ± 11.71 | 42.8 ± 11.72 | 44.8 ± 10.57 | 43.8 ± 11.34 |
| Sex: Female, Male(Participants) | Debio 1450 80 mg/120 mg BID | Debio 1450 160 mg/240 mg BID | Vancomycin/Linezolid BID | Total |
|---|---|---|---|---|
| Female | 36 | 35 | 32 | 103 |
| Male | 74 | 74 | 79 | 227 |
The record gives a start of May 2015, a primary completion of Aug 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2019, 3 years 3 months after primary completion. A results delay was requested in Aug 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Afabicin